PDS Biotechnology Corp — Director's Dealing 2017

Mar 7, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2017-03-06

Reporting Person: LOUGHLIN JAMES J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-06	Common Stock	P	3000	$9.24	Acquired	6000	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	19625	Direct

Footnotes

F1: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.